{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T10:36:05Z","timestamp":1786703765210,"version":"build-2736575974"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009448","name":"Universit\u00e0 degli Studi della Campania Luigi Vanvitelli","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009448","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To compare the clinical and microbiological outcomes of high-risk neutropenic patients receiving or not fluoroquinolone prophylaxis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study eligibility criteria<\/jats:title>\n                    <jats:p>Randomized controlled trials (RCTs) and observational studies investigating overall mortality and rate of febrile episodes, of bloodstream infections and of isolation of a fluoroquinolone-resistant strain among patients receiving or not prophylaxis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Patients with high-risk neutropenia due to haematological malignancies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions<\/jats:title>\n                    <jats:p>Prophylaxis with either ciprofloxacin or levofloxacin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Comparator<\/jats:title>\n                    <jats:p>\u00a0No prophylaxis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods of data synthesis<\/jats:title>\n                    <jats:p>We conducted a meta-analysis pooling risk ratios (RRs) through random effect models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 1731 articles screened, 18 original studies fulfilled the inclusion criteria and were included in the analysis, accounting for a total of 12,586 patients, 7157 (56.9%) of which receiving fluoroquinolones prophylaxis. The analysis assessing the primary outcome including 12,134 patients showed similar mortality rates between groups (RR 1.04, 95% CI 0.79\u20131.37,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.77), with a low statistical heterogeneity observed (I\n                      <jats:sup>2<\/jats:sup>\n                      49.4%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.022). These findings were confirmed (RR 1.16, 95% CI 0.89\u20131.50,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.27) in the sub-analysis excluding studies conducted in settings with low prevalence of fluoroquinolone resistance, on a total of 3121 patients, and a low heterogeneity was observed (I\n                      <jats:sup>2<\/jats:sup>\n                      27.6%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.18). Regarding the incidence of febrile episodes, a lower rate was observed among the 1701 patients receiving prophylaxis as compared to the 1514 not receiving prophylaxis (RR 0.87, 95% CI 0.88\u20130.96,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.006); similarly, a lower rate of bloodstream infections was demonstrated among subjects receiving fluoroquinolone prophylaxis (RR 0.59, 95% CI 0.47\u20130.75,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) in a meta-analysis including 11,681 patients. Finally, no difference in the isolation rate of fluoroquinolone resistant strains was observed (RR 0.87, 95% CI 0.34\u20132.20,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.77) among 1481 patients included.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our data suggest that fluoroquinolone prophylaxis in high-risk neutropenic patients is associated with a reduction in the incidence of febrile episodes and bacteraemia but does not provide a survival benefit.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s15010-026-02824-9","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T10:48:15Z","timestamp":1779878895000},"page":"1969-1980","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of fluoroquinolone prophylaxis in high-risk neutropenic patients with haematological malignancies: a systematic review with meta-analysis"],"prefix":"10.1007","volume":"54","author":[{"given":"Lorenzo","family":"Onorato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margherita","family":"Macera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariagrazia","family":"Palamone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Ambrisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Coppola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,27]]},"reference":[{"issue":"6","key":"2824_CR1","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1080\/14787210.2025.2487149","volume":"23","author":"C Bo\u015fnak","year":"2025","unstructured":"Bo\u015fnak C, Akova M. Febrile neutropenia management in high-risk neutropenic patients: a narrative review on antibiotic prophylaxis and empirical treatment. Expert Rev Anti Infect Ther. 2025;23(6):327\u201341. https:\/\/doi.org\/10.1080\/14787210.2025.2487149.","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"1","key":"2824_CR2","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.cmi.2024.09.015","volume":"31","author":"AG Er","year":"2025","unstructured":"Er AG, Aslan AT, Mikulska M, Akova M. Prevention and treatment of bacterial infections in patients with haematological cancers and haematopoietic stem cell transplantation: headways and shortcomings. Clin Microbiol Infect. 2025;31(1):24\u20138. https:\/\/doi.org\/10.1016\/j.cmi.2024.09.015.","journal-title":"Clin Microbiol Infect"},{"issue":"11","key":"2824_CR3","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1200\/JOP.18.00366","volume":"14","author":"RA Taplitz","year":"2018","unstructured":"Taplitz RA, Kennedy EB, Flowers CR. Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update summary. J Oncol Pract. 2018;14(11):692\u20135. https:\/\/doi.org\/10.1200\/JOP.18.00366.","journal-title":"J Oncol Pract"},{"issue":"suppl 5","key":"2824_CR4","doi-asserted-by":"publisher","first-page":"v111","DOI":"10.1093\/annonc\/mdw325","volume":"27","author":"J Klastersky","year":"2016","unstructured":"Klastersky J, de Naurois J, Rolston K, Rapoport B, Maschmeyer G, Aapro M, et al. Management of febrile neutropaenia: ESMO clinical practice guidelines. Ann Oncol. 2016;27(suppl 5):v111-8. https:\/\/doi.org\/10.1093\/annonc\/mdw325.","journal-title":"Ann Oncol"},{"issue":"1 B","key":"2824_CR5","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/j.1445-5994.2010.02342.x","volume":"41","author":"S Lingaratnam","year":"2011","unstructured":"Lingaratnam S, Slavin MA, Mileshkin L, Solomon B, Burbury K, Seymour JF, et al. An Australian survey of clinical practices in management of neutropenic fever in adult cancer patients 2009. Intern Med J. 2011;41(1 B):110\u201320. https:\/\/doi.org\/10.1111\/j.1445-5994.2010.02342.x.","journal-title":"Intern Med J"},{"issue":"8","key":"2824_CR6","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1002\/cncr.22205","volume":"107","author":"L Leibovici","year":"2006","unstructured":"Leibovici L, Paul M, Cullen M, Bucaneve G, Gafter-Gvili A, Fraser A, et al. Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions. Cancer. 2006;107(8):1743\u201351. https:\/\/doi.org\/10.1002\/cncr.22205.","journal-title":"Cancer"},{"issue":"10","key":"2824_CR7","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1056\/nejmoa044097","volume":"353","author":"G Bucaneve","year":"2005","unstructured":"Bucaneve G, Micozzi A, Menichetti F, Martino P, Dionisi MS, Martinelli G, et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med. 2005;353(10):977\u201387. https:\/\/doi.org\/10.1056\/nejmoa044097.","journal-title":"N Engl J Med"},{"key":"2824_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2535","volume":"339","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535. https:\/\/doi.org\/10.1136\/bmj.b2535.","journal-title":"BMJ"},{"issue":"1","key":"2824_CR9","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jinf.2017.10.009","volume":"76","author":"M Mikulska","year":"2018","unstructured":"Mikulska M, Averbuch D, Tissot F, Cordonnier C, Akova M, Calandra T, et al. Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines. J Infect. 2018;76(1):20\u201337. https:\/\/doi.org\/10.1016\/j.jinf.2017.10.009.","journal-title":"J Infect"},{"key":"2824_CR10","unstructured":"ECDC. European Centre for Disease Prevention and Control. Antimicrobial resistance in the EU\/EEA (EARS-Net). Annual Epidemiological Report 2023; Available at: https:\/\/www.ecdc.europa.eu\/en\/publications-data\/antimicrobial-resistance-eueea-ears-net-annual-epidemiological-report-2023- Last accessed: November 13, 2025."},{"key":"2824_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised Cochrane risk-of-bias tool for randomized trials. BMJ. 2019;366:14898. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"key":"2824_CR12","unstructured":"Wells G, Shea B, O\u2019Connell D, Peterson J, Welch V, Losos M. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2025."},{"issue":"3","key":"2824_CR13","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177\u201388. https:\/\/doi.org\/10.1016\/0197-2456(86)90046-2.","journal-title":"Control Clin Trials"},{"issue":"7109","key":"2824_CR14","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629\u201334.","journal-title":"BMJ"},{"issue":"2","key":"2824_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjid.2023.102745","volume":"27","author":"MC Dufrayer","year":"2023","unstructured":"Dufrayer MC, Rechenmacher C, Meneses CF, Monteiro YMC, Carlesse FADMC, Motta F, et al. Safety of levofloxacin as an antibiotic prophylaxis in the induction phase of children newly diagnosed with acute lymphoblastic leukemia: an interim analysis of a randomized, open-label trial in Brazil. Braz J Infect Dis. 2023;27(2):102745. https:\/\/doi.org\/10.1016\/j.bjid.2023.102745.","journal-title":"Braz J Infect Dis"},{"issue":"9","key":"2824_CR16","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1182\/bloodadvances.2022008226","volume":"7","author":"D Clerici","year":"2023","unstructured":"Clerici D, Galli L, Greco R, Lugli AP, Erbella F, Ripa M, et al. Levofloxacin prophylaxis vs no prophylaxis in patients with neutropenia within an endemic country for carbapenem-resistant GNB. Blood Adv. 2023;7(9):1621\u201334. https:\/\/doi.org\/10.1182\/bloodadvances.2022008226.","journal-title":"Blood Adv"},{"key":"2824_CR17","first-page":"159","volume":"15","author":"M Tabarraee","year":"2016","unstructured":"Tabarraee M, Tavakoli-Ardakani M, Mehdizadeh M, Ghadiani M, Rezvani H, Hajifathali A, et al. Oral ciprofloxacin prophylaxis in patients undergoing high dose therapy and autologous hematopoietic stem cell transplantation. Iran J Pharm Res. 2016;15:159\u201363.","journal-title":"Iran J Pharm Res"},{"issue":"7","key":"2824_CR18","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.cmi.2017.11.019","volume":"24","author":"M Yeshurun","year":"2018","unstructured":"Yeshurun M, Vaxman I, Shargian L, Yahav D, Bishara J, Pasvolsky O, et al. Antibacterial prophylaxis with ciprofloxacin for patients with multiple myeloma and lymphoma undergoing autologous haematopoietic cell transplantation: a quasi-experimental single-centre before-after study. Clin Microbiol Infect. 2018;24(7):749\u201354. https:\/\/doi.org\/10.1016\/j.cmi.2017.11.019.","journal-title":"Clin Microbiol Infect"},{"issue":"10","key":"2824_CR19","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1001\/jama.2018.12512","volume":"320","author":"S Alexander","year":"2018","unstructured":"Alexander S, Fisher BT, Gaur AH, Dvorak CC, Luna DV, Dang H, et al. Effect of levofloxacin prophylaxis on bacteremia in children with acute leukemia or undergoing hematopoietic stem cell transplantation a randomized clinical trial. JAMA. 2018;320(10):995\u20131004. https:\/\/doi.org\/10.1001\/jama.2018.12512.","journal-title":"JAMA"},{"issue":"12","key":"2824_CR20","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1016\/S1470-2045(19)30506-6","volume":"20","author":"MT Drayson","year":"2019","unstructured":"Drayson MT, Bowcock S, Planche T, Iqbal G, Pratt G, Yong K, et al. Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial. Lancet Oncol. 2019;20(12):1760\u201372. https:\/\/doi.org\/10.1016\/S1470-2045(19)30506-6.","journal-title":"Lancet Oncol"},{"issue":"1","key":"2824_CR21","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.jinf.2018.05.004","volume":"77","author":"WV Kern","year":"2018","unstructured":"Kern WV, Weber S, Dettenkofer M, Kaier K, Bertz H, Behnke M, et al. Impact of fluoroquinolone prophylaxis during neutropenia on bloodstream infection: data from a surveillance program in 8755 patients receiving high-dose chemotherapy for haematologic malignancies between 2009 and 2014. J Infect. 2018;77(1):68\u201374. https:\/\/doi.org\/10.1016\/j.jinf.2018.05.004.","journal-title":"J Infect"},{"issue":"12","key":"2824_CR22","doi-asserted-by":"publisher","first-page":"3289","DOI":"10.1093\/jac\/dkae360","volume":"79","author":"A Stern","year":"2024","unstructured":"Stern A, Henig I, Cohen M, Gur I, Henig O, Zuckerman T, et al. Impact of discontinuing routine fluoroquinolone prophylaxis in neutropenic allogeneic haematopoietic stem cell transplant recipients: an observational study. J Antimicrob Chemother. 2024;79(12):3289\u201396. https:\/\/doi.org\/10.1093\/jac\/dkae360.","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"2824_CR23","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaf105","volume":"12","author":"X Brousse","year":"2025","unstructured":"Brousse X, Rasandisona N, B\u00e9rard E, Leroy H, Delavigne K, Mottal N, et al. Levofloxacin to prevent bacterial infection in patients with acute myeloid leukemia treated by venetoclax and azacitidine: a Toulouse-Bordeaux DATAML registry study. Open Forum Infect Dis. 2025;12(3):ofaf105. https:\/\/doi.org\/10.1093\/ofid\/ofaf105.","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"2824_CR24","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae707","volume":"12","author":"D Leardini","year":"2025","unstructured":"Leardini D, Gambuti G, Muratore E, Baccelli F, Gottardi F, Venturelli F, et al. Levofloxacin prophylaxis in pediatric and young adult allogeneic hematopoietic stem cell transplantation recipients does not prevent infective complications and infections-related deaths. Open Forum Infect Dis. 2025;12(2):ofae707. https:\/\/doi.org\/10.1093\/ofid\/ofae707.","journal-title":"Open Forum Infect Dis"},{"key":"2824_CR25","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2023.1606","volume":"17","author":"A Ejaz","year":"2023","unstructured":"Ejaz A, Belgaumi AF, Alam SE, Ashraf MS, Raza MR. Effectiveness of levofloxacin in the induction of chemotherapy in high-risk acute lymphoblastic leukaemia in children in a developing country. ecancermedscience. 2023;17:1606. https:\/\/doi.org\/10.3332\/ecancer.2023.1606.","journal-title":"ecancermedscience"},{"issue":"1","key":"2824_CR26","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.1111\/ajco.12133","volume":"12","author":"M Ghadiany","year":"2016","unstructured":"Ghadiany M, Rahimi H, Rezvani H, Mohammad Alizadeh A, Zamani N, Mehdizadeh M, et al. Prophylaxis of neutropenic fever with ciprofloxacin in patients with acute myeloid leukemia treated with intensive chemotherapy. Asia Pac J Clin Oncol. 2016;12(1):e11-5. https:\/\/doi.org\/10.1111\/ajco.12133.","journal-title":"Asia Pac J Clin Oncol"},{"issue":"1","key":"2824_CR27","doi-asserted-by":"publisher","DOI":"10.4084\/MJHID.2023.022","volume":"15","author":"I Urbino","year":"2023","unstructured":"Urbino I, Frairia C, Busca A, Corcione S, D\u2019Ardia S, Dellacasa CM, et al. Levofloxacin prophylaxis versus no prophylaxis in acute myeloid leukemia during post-induction aplasia: a single center study. Mediterr J Hematol Infect Dis. 2023;15(1):e2023022. https:\/\/doi.org\/10.4084\/MJHID.2023.022.","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"2","key":"2824_CR28","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s00520-016-3436-3","volume":"25","author":"BR Ganti","year":"2017","unstructured":"Ganti BR, Marini BL, Nagel J, Bixby D, Perissinotti AJ. Impact of antibacterial prophylaxis during reinduction chemotherapy for relapse\/refractory acute myeloid leukemia. Support Care Cancer. 2017;25(2):541\u20137. https:\/\/doi.org\/10.1007\/s00520-016-3436-3.","journal-title":"Support Care Cancer"},{"issue":"12","key":"2824_CR29","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.clml.2022.08.001","volume":"22","author":"J Caro","year":"2022","unstructured":"Caro J, Madero-Marroquin R, Zubizarreta N, Moshier E, Tremblay D, Coltoff A, et al. Impact of fluoroquinolone prophylaxis on neutropenic fever, infections, and antimicrobial resistance in newly diagnosed AML patients. Clin Lymphoma Myeloma Leuk. 2022;22(12):903\u201311. https:\/\/doi.org\/10.1016\/j.clml.2022.08.001.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"2824_CR30","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1007\/s00520-017-3976-1","volume":"26","author":"SSF Lee","year":"2018","unstructured":"Lee SSF, Fulford AE, Quinn MA, Seabrook J, Rajakumar I. Levofloxacin for febrile neutropenia prophylaxis in acute myeloid leukemia patients associated with reduction in hospital admissions. Support Care Cancer. 2018;26(5):1499\u2013504. https:\/\/doi.org\/10.1007\/s00520-017-3976-1.","journal-title":"Support Care Cancer"},{"issue":"2","key":"2824_CR31","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1177\/1078155217735153","volume":"25","author":"AB Clemmons","year":"2019","unstructured":"Clemmons AB, Gandhi AS, Albrecht B, Jacobson S, Pantin J. Impact of fluoroquinolone prophylaxis on infectious-related outcomes after hematopoietic cell transplantation. J Oncol Pharm Pract. 2019;25(2):326\u201332. https:\/\/doi.org\/10.1177\/1078155217735153.","journal-title":"J Oncol Pharm Pract"},{"issue":"12","key":"2824_CR32","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1111\/ctr.12635","volume":"29","author":"HA Hafez","year":"2015","unstructured":"Hafez HA, Yousif D, Abbassi M, Elborai Y, Elhaddad A. Prophylactic Levofloxacin in pediatric neutropenic patients during autologous hematopoietic stem cell transplantation. Clin Transplant. 2015;29(12):1112\u20138. https:\/\/doi.org\/10.1111\/ctr.12635.","journal-title":"Clin Transplant"},{"issue":"6","key":"2824_CR33","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1093\/cid\/ciz319","volume":"70","author":"G Martinez-Nadal","year":"2020","unstructured":"Martinez-Nadal G, Puerta-Alcalde P, Gudiol C, Cardozo C, Albasanz-Puig A, Francesc M, et al. Inappropriate empirical antibiotic treatment in high-risk neutropenic patients with bacteremia in the era of multidrug resistance. Clin Infect Dis. 2020;70(6):1068\u201374. https:\/\/doi.org\/10.1093\/cid\/ciz319.","journal-title":"Clin Infect Dis"},{"key":"2824_CR34","unstructured":"Assessorato alla sanit\u00e0 della Regione Campania - Direzione Generale per la Tutela della Salute ed il Coordinamento del Sistema Sanitario Regionale. Rapporto 2022 sull\u2019antibiotico resistenza. 2023, Available at: https:\/\/www.regione.campania.it\/regione\/it\/tematiche\/antibiotico-resistenza-ed-infezioni-correlate-all-assistenza-64in\/antibiotico-resistenza-ed-infezioni-correlate-all-assistenza-r11p?page=1. Last accessed: November 13, 2025."},{"issue":"9","key":"2824_CR35","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1016\/j.cmi.2022.03.014","volume":"28","author":"G Sulis","year":"2022","unstructured":"Sulis G, Sayood S, Katukoori S, Bollam N, George I, Yaeger LH, et al. Exposure to World Health Organization\u2019s AWaRe antibiotics and isolation of multidrug resistant bacteria: a systematic review and meta-analysis. Clin Microbiol Infect. 2022;28(9):1193\u2013202. https:\/\/doi.org\/10.1016\/j.cmi.2022.03.014.","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"2824_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.idnow.2025.105064","volume":"55","author":"AP Jonville-B\u00e9ra","year":"2025","unstructured":"Jonville-B\u00e9ra AP, Largeau B, di Meglio F, Pariente A. The safety profile of fluoroquinolones. Infect Dis Now. 2025;55(4):105064. https:\/\/doi.org\/10.1016\/j.idnow.2025.105064.","journal-title":"Infect Dis Now"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-026-02824-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-026-02824-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-026-02824-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T10:10:06Z","timestamp":1786702206000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-026-02824-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,27]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["2824"],"URL":"https:\/\/doi.org\/10.1007\/s15010-026-02824-9","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,27]]},"assertion":[{"value":"31 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable because systematic review.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}